News | November 07, 2022
Rossari Biotech Q2 FY23 revenue up 11%; Profit down 9%
H1 FY23 revenues at Rs. 860.1 crore, higher by 40% YoY whereas PAT at Rs. 52.6 crore, higher by 4% YoY
H1 FY23 revenues at Rs. 860.1 crore, higher by 40% YoY whereas PAT at Rs. 52.6 crore, higher by 4% YoY
The laboratory is equipped to perform high-volume diagnostic testing services
API platform to comprise of RA Chem Pharma, ZCL Chemicals and Avra Laboratories
Most of the new growth Capex investments are happening on the Specialty Chemicals and Nutrition side
Menon has over 41 years of diverse experience in some of the premier multinational and Indian companies in the chemical and power industry
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
He has over 23 years' experience working in leading companies such as Omniactive Health Technologies, Johnson Matthey Chemicals, BASF, Godrej Agrovet Limited & Bharat Petroleum Corporation Limited.
The JUMP-CP Consortium’s aim is to validate and scale up image-based drug discovery strategies by creating the world’s largest public cell imaging data set
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
The new plant will include a wide range of dosage form capabilities for oral solids, liquids, topicals, films, and manufacturing technologies for granulation, film coating, spray drying, tableting
Subscribe To Our Newsletter & Stay Updated
